Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease

The U.S. Food and Drug Administration (FDA) recently approved pembrolizumab, an anti- programmed cell death protein 1 cancer immunotherapeutic, for use in advanced solid tumors in patients with the microsatellite-high/DNA mismatch repair-deficient biomarker. This is the first example of a tissue-agn...

Descripción completa

Detalles Bibliográficos
Autores principales: Boyiadzis, Michael M., Kirkwood, John M., Marshall, John L., Pritchard, Colin C., Azad, Nilofer S., Gulley, James L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5950135/
https://www.ncbi.nlm.nih.gov/pubmed/29754585
http://dx.doi.org/10.1186/s40425-018-0342-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5950135/
https://www.ncbi.nlm.nih.gov/pubmed/29754585
http://dx.doi.org/10.1186/s40425-018-0342-x

Ejemplares similares